Journal
JOURNAL OF CLINICAL ONCOLOGY
Volume 22, Issue 18, Pages 3776-3783Publisher
AMER SOC CLINICAL ONCOLOGY
DOI: 10.1200/JCO.2004.12.082
Keywords
-
Categories
Ask authors/readers for more resources
Purpose This phase III, randomized, open-label, multicenter study compared the overall survival associated with irinotecan plus gemcitabine (IRINOGEM) versus gemcitabine monotherapy (GEM) in patients with chemotherapy-naive, locally advanced or metastatic pancreatic cancer. Patients and Methods IRINOGEM patients received starting doses of gemcitabine 1,000 mg/m(2) and irinotecan 100 mg/m(2) given weekly for 2 weeks every 3-week cycle. GEM patients received gemcitabine 1,000 mg/m(2) weekly for 7 of 8 weeks (induction) and then weekly for 3 of 4 weeks. The primary end point of the trial was survival. Secondary end points included tumor response, time to tumor progression (TTP), changes in CA 19-9, and safety. Results In each arm, 180 randomly assigned patients comprised the intent-to-treat population evaluated for efficacy; 173 IRINOGEM and 169 GEM patients were treated. Median survival times were 6.3 months for IRINOGEM (95% Cl, 4.7 to 7.5 months) and 6.6 months for GEM (95% Cl, 5.2 to 7.8 months; log-rank P = .789). Tumor response rates were 16.1% (95% Cl, 11.1% to 22.3%) for IRINOGEM and 4.4% (95% Cl, 1.9% to 8.6%) for GEM (chi(2) p <. 001). Median TTP was 3.5 months for IRINOGEM versus 3.0 months for GEM (log-rank P = .352). However, subset analyses in patients with locally advanced disease suggested a TTP advantage with IRINOGEM versus GEM (median, 7.7 v 3.9 months). CA 19-9 progression was positively correlated with tumor progression. The incidence of grade 3 diarrhea was higher in the IRINOGEM group but grade 3 to 4 hematologic toxicities and quality-of-life outcomes were similar. Conclusion IRINOGEM safely improved the tumor response rate compared with GEM but did not alter overall survival. (C) 2004 by American Society of Clinical Oncology.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available